Investigational therapies in the treatment of obesity

Area of Science:

• Endocrinology and Metabolism
• Neuroscience
• Public Health

Background:

• Obesity is a significant global health challenge with environmental contributors.
• The hypothalamus plays a crucial role in regulating energy balance and body weight.
• Dysregulation of hypothalamic pathways can lead to significant weight fluctuations.

Purpose of the Study:

• To review and comment on investigational antiobesity medications.
• To explore how these drugs modulate energy homeostasis.
• To categorize drugs based on their mechanism of action (stimulating catabolic or inhibiting anabolic pathways).

Main Methods:

• Review of scientific literature on investigational antiobesity medications.
• Categorization of drugs based on their targets within energy homeostasis pathways.
• Analysis of mechanisms of action for weight reduction.

Main Results:

• Identified numerous investigational drugs targeting hypothalamic pathways for weight management.
• Classified drugs into those stimulating catabolic pathways (e.g., leptin, GLP-1 agonists) and those inhibiting anabolic pathways (e.g., ghrelin antagonists, cannabinoid-1 receptor antagonists).
• Highlighted diverse pharmacological approaches to modulating energy balance.

Conclusions:

• Investigational antiobesity medications offer promising strategies for weight reduction by targeting specific energy homeostasis pathways.
• Understanding these diverse mechanisms is crucial for developing effective obesity treatments.
• Future research should focus on the efficacy and safety of these novel therapeutic agents.